There are moments in the market where a high-quality company quietly falls out of favour.
Not because its long-term story has disappeared, but because short-term issues start to dominate the narrative.
That is how I see CSL Ltd (ASX: CSL) right now.
After falling more than 40% over the past year, this is no longer a biotechnology stock riding momentum. It is one that is being questioned. And for me, that is exactly when it becomes interesting.
Image source: Getty Images
A weaker period, but not a broken business
There is no denying that CSL has had a difficult stretch.
Its latest half-year result showed softer performance, with underlying profit declining and revenue slightly lower, impacted by policy changes, restructuring costs, and impairments.
On the surface, that explains why the share price has struggled.
But when I look a bit deeper, I do not see a business in decline. I see one going through a reset.
Management has been very clear that it is not satisfied with recent performance and is actively implementing changes to improve growth and efficiency.
That matters. Because I think this is less about structural weakness and more about execution, transition, and short-term disruption.
The turnaround is already underway
What stands out to me most is that CSL is not standing still.
The company is progressing a transformation program focused on simplifying operations, reducing costs, and investing in future growth. It has already achieved a significant portion of its targeted cost savings and expects meaningful efficiency gains over the coming years.
At the same time, it is continuing to invest in its pipeline.
For example, its licensing agreement with Eli Lilly and Co (NYSE: LLY) for clazakizumab highlights ongoing efforts to develop new therapies and expand its product offering.
This is what I would expect from a global healthcare leader.
It is addressing current challenges while still positioning itself for long-term growth.
Why the risk-reward looks attractive for CSL shares
When a stock falls 40% or more, expectations tend to reset.
That can create an interesting setup.
If things continue to deteriorate, the downside may be more limited if expectations are already low. But if the business stabilises and begins to improve, the upside can be significant.
CSL still operates in areas like plasma therapies, vaccines, and specialty pharmaceuticals. These are not short-term trends. They are long-term healthcare needs.
The company is also guiding for a stronger second half, supported by key therapies and newly launched products.
That tells me the growth story has not disappeared.
It has just become less linear.
This is where patience comes in
I do not expect CSL and its shares to bounce back overnight.
Turnarounds take time. Execution matters. And there may still be volatility ahead.
But when I look out over the next five to ten years, I think the current share price starts to look far more interesting than it did a year ago.
This is a business with global scale, deep expertise, and products that address serious medical needs.
Those characteristics do not disappear because of one difficult year.
Foolish takeaway
I think CSL shares are entering a phase where long-term investors should start paying close attention.
The past year has been disappointing. There is no getting around that. But with the share price down more than 40%, a transformation program underway, and growth expected to improve, I believe the risk-reward has shifted.
For me, this is exactly the type of situation where it can make sense to start leaning in.
